Email us today +

Every year in the U.S.A., 99,000 men and 78,000 women develop lung cancer. Only 14% of them are still alive five years later. But if the lung cancer is localized at the time of diagnosis, and treated promptly, the five-year survival rate is increased more than threefold. Consequently, an early screening test has the potential to reduce the death rate from lung cancer.

This R&D was funded by SBIR Phase I, II, and III grants from the National Institutes of Health (NIH). With NIH support, we are now performing a larger confirmatory study of the breath test designed to obtain FDA approval. The patient recruitment phase of this study is nearly completed. Patients have been recruited from these sites:

Christiana Hospital, Newark, DE

MD Anderson Cancer Center Orlando, Orlando, FL

New York University Medical Center, New York, NY

Seattle Swedish Cancer Institute, Seattle, WA

Weill Cornell Medical Center, New York, NY

This study is listed at clinicaltrials.gov.

Publications

(PDF Document) Detection of Lung Cancer Using Weighted Digital Analysis of Breath Biomarkers.

Phillips M, Altorki N, Austin JHM, Cameron RB, Cataneo RN, Kloss R, Maxfield RA, Munawar MI, Pass HI, Rashid A, Rom WN, Schmitt P, Wai J

Clinica Chimica Acta ref. CCA10989 (May 31, 2008)

(PDF Document) Prediction of lung cancer using volatile biomarkers in breath.

Phillips M, Altorki N, Austin JHM, Cameron RB, Cataneo RN, Greenberg J, Robert Kloss R, Maxfield RA, Munawar MI, Pass HI, Rashid A, Rom WN, and Schmitt P

Cancer Biomarkers (2007); 3: 95-109.

(PDF Document) Prediction of Lung Cancer Using Volatile Biomarkers in Breath.

Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, Greenburg J, Kloss R, Maxfield RA, Pass HI, Rom WN, and Tietje O

Journal of Clinical Oncology 2005; 23(16S): 839 S. Floor presentation at 2005 ASCO Annual Meeting, Orlando, Florida, May 16, 2005

(PDF document) Detection of lung cancer with volatile markers in the breath.

Phillips M, Cataneo RN, Cummin ARC, Gagliardi AJ, Gleeson K, Greenberg J, Maxfield RA, Rom WN

Chest (2003); 123: 2115-2123

(PDF document) Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study.

Phillips M, Gleeson K, Hughes JMB, Greenberg J, Cataneo RN, Baker L and McVay WP

Lancet (1999); 353: 1930-33. Commentary Lancet (1999); 353: 1897-1898